Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343052 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL19355185 | 0.85 | CYP2D6 (0.42) | SMN1; SMN2LMNAKDM4EHSD17B10DUSP3 | |
| SCHEMBL12116102 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL21674072 | 0.82 | CHRNB2 (0.44) | SMN1; SMN2LMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL4611409 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL19656717 | 0.82 | TSHR (0.38) | SMN1; SMN2LMNATSHRKDM4EDUSP3 | |
| SCHEMBL19355183 | 0.81 | GAA (0.43) | SMN1; SMN2LMNAALDH1A1TSHRKDM4E | |
| Ammonia Solution, Strong SCHEMBL9998724 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL19656636 | 0.80 | ADRB2 (0.36) | — | |
| SCHEMBL17793976 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | CATABASIS PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | NDUFAB1, ATG7, HADHA | SMN1; SMN2 229/4885LMNA 2779/4885ALDH1A1 1342/4885 |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | NDUFAB1, ATG7, NLN | SMN1; SMN2 237/4885LMNA 2734/4885ALDH1A1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.